# International Study on COVID-19 Vaccine to Assess Immunogenicity, Reactogenicity and Efficacy (InVITE)

> **NCT05096091** · — · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 5399 (actual)

## Conditions studied

- COVID-19

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT05096091
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-08-16
- **Primary completion:** 2025-08-19
- **Final completion:** 2025-08-19
- **Target enrollment:** 5399 (ACTUAL)
- **Last updated:** 2025-12-18

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05096091

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05096091, "International Study on COVID-19 Vaccine to Assess Immunogenicity, Reactogenicity and Efficacy (InVITE)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05096091. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*